pembrolizumab,bevacizumab
merck,roche
['bevacizumab', 'kn-826']
impressive long term results of kn-826 in cervical cancer. almost 30% of patients remain long term progression-free!!! result independent of bevacizumab administration. os 28 months in the approved pd-l1 cps&gt;1 population. #asco23 
Ασυνάρτητος και ημιτελής. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.